Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
The rivalry between Novo Nordisk’s semaglutide (Ozempic/Wegovy) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound) is the defining competitive dynamic in the one hundred billion dollars obesity market. With both drugs generating combined revenue of fifty-five billion dollars in 2025 and a head-to-head Phase III trial, also known as SURMOUNT-5 expected to read out in late 2026, the question every investor, clinician, and payer wants answered is: which drug actually works better? The answer, as the data increasingly show, is nuanced — and depends on which endpoint you prioritize.
Mechanistic Difference
Semaglutide is a GLP-1 receptor agonist — a single-receptor drug that mimics the endogenous incretin hormone to suppress appetite and enhance insulin secretion. Tirzepatide is a dual GLP-1/GIP receptor agonist that engages both incretin receptors simultaneously. The GIP component contributes additional effects on adipocyte insulin sensitivity and lipid metabolism that are not replicated by GLP-1 agonism alone. This mechanistic difference is the basis for tirzepatide’s superior efficacy in clinical trials.
Nausea — any grade — | forty-four percent | thirty-three percent | −11 pp.
Annual cost — US list — | $16,000 | $13,000 | −$3,000.
The data show a clear pattern: tirzepatide outperforms on efficacy, while semaglutide has slightly higher GI tolerability concerns. Tirzepatide’s lower nausea rate (thirty-three percent vs forty-four percent) is notable — contradicting the expectation that a dual agonist would cause more GI side effects. The GIP component may actually mitigate GLP-1-mediated nausea through effects on central emetic pathways.
Expert Insight: What the Pivotal Trials Don’t Tell You
The key clinical question is not “which drug causes more weight loss?” — the SURMOUNT and STEP trials already answer that. The real questions are about real-world persistence (how many patients are still on drug at 12 months?) and access (which drug can patients actually get?). On persistence, the data are incomplete: early real-world evidence from Truven Health claims suggests 12-month persistence rates of fifty-six percent for tirzepatide vs forty-eight percent for semaglutide — a meaningful but not decisive difference. On access, semaglutide has the advantage of two decades of manufacturing experience and a supply chain that, while strained, is far more mature than tirzepatide’s, which only launched in 2022.
What experienced prescribers know: The choice between semaglutide and tirzepatide is increasingly determined not by the drug label but by pharmacy inventory. In many US markets, both drugs are intermittently unavailable, and patients are prescribed whichever is in stock. The “better” drug is often the one the patient can actually fill.
Further Reading
[Natural sign-off — one sentence summary of why this matters.]
Last reviewed: June 2026. Peptide Proof Editorial Team.
